T Yin1, W Li1, P Zhao1, Y Wang1, J Zheng2. 1. Center of Interventional Oncology and Liver Diseases, Beijing You'an Hospital, Capital Medical University, Beijing 100069, PR China. 2. Center of Interventional Oncology and Liver Diseases, Beijing You'an Hospital, Capital Medical University, Beijing 100069, PR China. Electronic address: zhengjiasheng6@sina.com.
Abstract
AIM: To evaluate the treatment efficacy and potential complications of computed tomography (CT)-guided microwave ablation for primary hepatocellular carcinoma (HCC). MATERIALS AND METHODS: Data were collected and analysed from 220 HCC patients treated with CT-guided microwave ablation and followed up for 2 years. Independent risk factors for overall survival and progression-free survival (PFS) were analysed. RESULTS: Among all cases followed, the cumulative overall survival rates at 1 and 2 years were 95.45% and 89.09%. The cumulative 1- and 2-year PFS rates were 80.90% and 62.73%. For patients with Barcelona Clinic Liver Cancer (BCLC) class C (n=60), the cumulative 1- and 2-year overall survival rates were 89.09% and 74.54%. In this group, patients with tumour invasion of blood vessels or tumour-related symptoms suffered a worse overall survival compared to those without (p=0.011). No fatal complications were observed. Child-Pugh score (p=0.030) and BCLC class (p=0.012) were independent risk factors for overall survival. The number of tumour nodules was an independent risk factor for reoccurrence. CONCLUSION: CT-guided percutaneous microwave ablation could be an effective and safe treatment option for HCC patients.
AIM: To evaluate the treatment efficacy and potential complications of computed tomography (CT)-guided microwave ablation for primary hepatocellular carcinoma (HCC). MATERIALS AND METHODS: Data were collected and analysed from 220 HCCpatients treated with CT-guided microwave ablation and followed up for 2 years. Independent risk factors for overall survival and progression-free survival (PFS) were analysed. RESULTS: Among all cases followed, the cumulative overall survival rates at 1 and 2 years were 95.45% and 89.09%. The cumulative 1- and 2-year PFS rates were 80.90% and 62.73%. For patients with Barcelona Clinic Liver Cancer (BCLC) class C (n=60), the cumulative 1- and 2-year overall survival rates were 89.09% and 74.54%. In this group, patients with tumour invasion of blood vessels or tumour-related symptoms suffered a worse overall survival compared to those without (p=0.011). No fatal complications were observed. Child-Pugh score (p=0.030) and BCLC class (p=0.012) were independent risk factors for overall survival. The number of tumour nodules was an independent risk factor for reoccurrence. CONCLUSION: CT-guided percutaneous microwave ablation could be an effective and safe treatment option for HCCpatients.
Authors: Eva Braunwarth; Peter Schullian; Moritz Kummann; Simon Reider; Daniel Putzer; Florian Primavesi; Stefan Stättner; Dietmar Öfner; Reto Bale Journal: PLoS One Date: 2022-01-04 Impact factor: 3.240